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Abstract
The Aspirin/Folate Polyp Prevention Study is a randomized, placebo-controlled trial of aspirin use
and folic acid supplementation and incidence of colorectal adenomas in individuals with a history
of these lesions. The trial showed that folic acid supplementation does not prevent the occurrence of
new adenomas and may increase risk. We extend these results by investigating whether the effect of
folic acid treatment differed by baseline dietary and circulating folate levels. Diet and supplement
use were ascertained at baseline through a food-frequency questionnaire; a blood sample was used
to determine plasma and red blood cell (RBC) folate levels. Individuals were followed for 3 years
(1st follow up) and subsequently for an additional 3-5 years (2nd follow up). We used generalized
linear regression to estimate risk ratios and 95% confidence limits as measures of association. There
was little evidence that baseline dietary and total folate intake, and plasma and RBC folate modified
the association between folic acid treatment and risk of any adenomas or advanced lesions. However,
there was a protective association of the highest tertile of dietary and total intake as well as circulating
folate with risk of any adenomas among those in the placebo group, but no association among
individuals in the folic acid group. Our findings support the idea that while moderate doses of folate
may be protective compared to deficiency, at some point of sufficiency supplementation provides
no additional benefit.
Keywords
Folate; dietary; plasma; folic acid; supplementation; colorectal adenomas; clinical trial
NIH Public Access
Author Manuscript
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2009 October 1.
Published in final edited form as:















Extensive epidemiologic data have supported a chemopreventive effect of folate on risk of
colorectal adenoma and cancer (1). However, in several animal studies, folic acid
supplementation has enhanced the development and progression of existing pre-malignant and
malignant lesions (2). Also, in our randomized clinical trial of folic acid supplementation of 1
mg/day with and without aspirin on the risk of incident colorectal adenomas there was no
reduction in risk overall, but a significant increased risk for advanced lesions and multiple
adenomas among individuals randomized to the folic acid treatment group after an average of
six years follow-up (3). In addition, an ecologic analysis of folic acid supplementation in the
United States and Canada reported data suggesting a temporal association between fortification
and an increase in colorectal cancer rates (4).
Several editorials have been published to highlight the evidence from animal and human studies
on the potential adverse consequences of folic acid supplementation (2,5–8). It is becoming
apparent that the timing and dose of folate exposure may be critical; high levels may promote
carcinogenesis in the presence of pre-existing neoplastic lesions (8). Therefore, there is concern
about the safety of chronic high intakes of folate (5), especially when there are a growing
number of cancer survivors who each may harbor residual transformed cells (9).
In this study, we extend the findings of our randomized clinical trial (3) by investigating
whether the association between folic acid treatment and adenomas differs by baseline dietary
and circulating folate levels. We hypothesized that individuals with high dietary intake or
circulating levels of folate may have a greater risk of new adenomas if supplemented with folic
acid compared to those with lower dietary folate intake or circulating levels. Secondly, based
on previous observational studies, we hypothesized that there may be a protective association
of higher dietary or circulating folates with risk among individuals in the placebo group, but
not in the folic acid treatment group.
Methods
Study Design
The Aspirin/Folate Polyp Prevention Study (AFPPS) is a randomized, double-blind, placebo-
controlled trial of the efficacy of oral aspirin, folic acid, or both to prevent colorectal adenomas
in patients with a history of adenomas at nine clinical centers (10). The trial had a three-by-
two factorial design, comparing 81 mg/day and 325 mg/day aspirin with placebo and comparing
1 mg/day folic acid with placebo. Originally, the trial was designed to investigate only aspirin,
but shortly after enrolment began, it was expanded to examine folic acid (100 individuals were
randomized before the folic acid component was initiated). The study protocol was approved
by the Institutional Review Board at all clinical centers and written informed consent was
obtained from all study participants. The findings regarding aspirin and folate have been
reported (3,10).
Study Population – Randomization, Interventions and Follow-Up
Potential participants were recruited between July 1994 and March 1998. Eligible individuals
had at least one of the following: one or more histologically confirmed adenomas removed
within 3 months before recruitment, one or more histologically confirmed adenomas removed
within 16 months before recruitment and a lifetime history of two or more confirmed adenomas,
or a histologically confirmed adenoma at least 1 cm in diameter removed within 16 months
before recruitment. After completion of a 3-month aspirin run-in period, compliant individuals
who wished to continue participating were randomized in a 1:1 ratio to 1 mg per day of folic
acid or placebo within strata defined by study center, sex and age (60 years or younger vs. older
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than 60 years). The period of treatment and follow-up was originally planned to be 3 years
(first follow-up interval); however, because of concern that longer exposure to folic acid might
be required to observe an anti-neoplastic effect, participants were asked to continue protocol
folate treatment for a second colonoscopic surveillance cycle (usually 3 or 5 years) (second
follow-up interval). Thus, two surveillance intervals were included in this analysis. When a
surveillance colonoscopy was not performed at the end of the first follow-up interval, we used
the last examination at least one year after randomization, on or before September 28, 2001 to
delineate the end of the first follow-up interval. The second follow-up interval was defined as
the time from the end of the first interval through the next surveillance colonoscopy on or
before December 31, 2006; however, folic acid treatment ended October 1, 2004 because of
funding constraints.
Data Collection
Questionnaires – Risk Factors and Diet—All participants completed a questionnaire
regarding personal characteristics, medical history and lifestyle habits. Dietary information
was collected using the Block food frequency questionnaire administered to participants at
baseline and at first follow-up. The validity and reliability of the food frequency questionnaire
has been described previously (11). Questions assessed the average consumption of a food item
during the past year. Brand and type of multivitamin supplement use were collected. Daily
nutrient intakes were calculated by multiplying the frequency response by the nutrient content
of the specified portion size using a comprehensive database. Total alcohol intake per day was
calculated as the sum of alcohol content from beer, wine and liquor.
Measurement of plasma and RBC folate—Blood samples were obtained from subjects
at baseline and at first follow-up from non-fasting participants into 7-ml EDTA Vacutainer
brand tubes. Plasma levels of folate were determined by a microbiological assay using a colistin
sulphate resistant strain of Lactobacillus leichmannii (12). EDTA samples with low (<2 nmol/
L) or no folate, attributable to inhibition of bacterial growth by antibiotics, were reanalyzed
with a method based on measurement of folate as p-aminobenzoylglutamate equivalents (13).
Red blood cell (RBC) folate was determined by the ACS:180® folate assay, a competitive
immunoassay using direct chemiluminescent technology (Bayer Corporation, Tarrytown NY).
Plasma folate was conducted at BEVITAL AS, Bergen, Norway.
Study Outcomes—Adenoma occurrence was determined by colonoscopy and pathology
review. All important medical events reported by participants were verified with medical
record review. Records for all large bowel procedures (endoscopy or surgery) were obtained.
Slides for all tissue removed from the bowel were obtained and sent to a single study pathologist
for uniform review. Lesions were classified as neoplastic (adenomatous, including sessile
serrated adenomas) or non-neoplastic.
The primary study outcome was the occurrence of one or more colorectal adenomas detected
during each of the 2 follow-up intervals. A secondary outcome was advanced lesions, defined
as invasive carcinoma or adenomas with at least 25% villous component, high grade dysplasia,
or estimated adenoma size of 1 centimeter or greater (as determined by the endoscopist).
Statistical Methods
Spearman's rank correlation coefficient was used to calculate correlations among baseline
measures of folate status: dietary folate intake, total folate intake (diet plus supplements),
plasma folate levels, and RBC folate levels. Over-dispersed generalized linear models for the
Poisson family as an approximation to the binomial family were used to compute crude and
adjusted risk ratios to assess the risk of at least one new adenoma. We computed risk ratios for
folic acid treatment versus placebo within strata (i.e., tertiles) defined by baseline levels of
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dietary, total intake, plasma and RBC folate. For nutrient analysis, we computed quartiles from
the residuals of the regression of the logarithm of folate intake on the logarithm of kilocalories
and used the logarithm of caloric intake to adjust for energy intake. Covariates included in the
models were age, sex, center, aspirin treatment group, baseline multivitamin use, and duration
of follow-up. In addition, for dietary measures, we adjusted for log calories. We included
multivitamin use in our final models as an indirect adjustment for other nutrients/ vitamins and
unknown lifestyle factors, although exclusion of this variable from adjusted models did not
substantially change any of the results. For plasma measures, we also adjusted for time from
blood draw to measurement (years), but since there was no significant change in the estimates
of risk we did not include this variable in final models. Models for the 2nd follow-up interval
were also adjusted for the following covariates: alcohol consumption, smoking status, body
mass index, family history of colorectal cancer, B2, B6 and B12and red meat consumption, but
no significant evidence of confounding was observed. We used interaction terms and Wald
tests (with or without adjustment for other variables) to test for heterogeneity by baseline folate
levels. Similarly, to investigate whether fortification of the food supply with folic acid
significantly affected these results we stratified the population recruited prior to and after
December 31, 1996 (mid point between years folic acid was introduced in U.S. and Canada)
but observed no evidence of effect modification and therefore present results on all participants.
We used the same approach to determine the association between tertiles of baseline dietary,
total intake, plasma and RBC folate and adenoma risk. We obtained risk ratio estimates
stratified by randomized folic acid treatment group, and used interaction terms and Wald tests
to test for evidence of interaction. When investigating the risk of advanced lesions we
dichotomized levels of dietary, total, plasma and RBC folate at the median, due to our limited
sample size. We also examined the role of dietary and total folate intake levels at first follow-
up and risk of any adenoma or advanced lesions in the second follow-up cycle, but our results
did not differ substantially from results examining the association with baseline measures (data
not shown).
All analyses of study folate treatment were conducted according to the principle of intention
to treat. Two-sided p-values less then 0.05 were considered statistically significant. Stata
(version 9.2) was used for all analyses.
Results
Characteristics of study participants
Among the 1,021 individuals randomized to folate treatment, 987 had a follow-up exam during
the first follow-up interval and, of these, 427 (43.3%) had a recurrence of one or more colorectal
adenoma. There were 926 individuals who continued in this clinical trial for a second follow-
up interval; 729 (71.4%) continued treatment. Overall, 762 had a surveillance colonoscopy
during the second follow-up interval and 295 (39%) had a recurrence. Individuals who
completed the first follow-up interval did not differ significantly from those who completed
the second follow-up on selected personal characteristics (Table 1).
Dietary and circulating folates were significantly correlated at baseline and also at first follow-
up (rho values range: 0.16-0.64, p values<0.0001). Plasma folate levels increased significantly
from baseline to first follow-up in the placebo group (mean ± SD = 23.7±17.0 vs. 29.9±14.3
nmol/L, p<0.0001) and much more markedly with folic acid treatment (mean ± SD=24.1±18.2
vs. 74.5 ± 35.8 nmol/L, p<0.0001).
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Association of folic acid treatment and risk of colorectal adenomas stratified by baseline
dietary, total intake, plasma and RBC folate levels
Table 2 shows the association of randomized folic acid treatment with adenoma risk, stratified
by levels of the baseline folate measures/indices. During the first follow-up interval, folic acid
treatment was not associated with risk of any adenoma among subjects with low levels of
dietary, total intake, plasma and RBC folate (Table 2). However, there were small, non-
significant increased risks associated with folic acid treatment at the highest tertile levels of
baseline total intake and high plasma folate levels. The difference between the folic acid RR
at the lowest (RR=0.85, 95% CI=0.67-1.09) and highest tertile (RR=1.46, 95% CI=1.12-1.89)
of baseline total folate intake reached statistically significance (p for interaction = 0.01). For
advanced lesions, the RR's for study folic acid treatment were statistically similar across tertiles
of folate status. During the second follow-up interval, the folic acid RR's did not differ by
baseline folate status. When we stratified by baseline multivitamin use, results were broadly
similar among multivitamin users and non-users (data not shown).
Association of baseline dietary/total intake and plasma/RBC folate and risk of adenomas
stratified by folic acid treatment group
Among subjects randomized to folic acid, there were no suggestions that baseline folate status
was associated with risk of all adenomas (Table 3). In contrast, among those randomized to
placebo, there were indications of inverse associations for all measures of folate status, and
this was statistically significant for total folate intake (RR for third tertile versus first = 0.69,
95% CI, 0.51-0.94; p for trend = 0.01) and for plasma folate levels (RR for third tertile versus
first = 0.72, 95% CI, 0.54-0.97, p for trend = 0.03). However, there was statistically significant
evidence for heterogeneity between the treatment groups only for total folate intake (p = 0.01).
The patterns in the second follow-up interval were not the same as in the first interval. During
this later period, there was a significant trend of increasing risk with increasing RBC folate
among placebo subjects (p=0.02), and a borderline increasing trend with dietary folate among
those randomized to folic acid (p=0.05). There was no indication of significant heterogeneity
by randomized treatment group.
For advanced adenomas, we found no evidence of that baseline folate intake or circulating
levels were significantly associated with risk and no evidence that these associations were
modified by folic acid treatment group (data not shown). We observed similar findings for
baseline folate status and risk of any adenoma and advanced lesions when stratified by baseline
multivitamin use.
Discussion
In this report, we extend the analyses from our earlier report (3) regarding the effect of folic
acid supplementation on risk of colorectal adenomas, by putting those results into the context
of the baseline folate status of the subjects. We found little indication that folic acid treatment
prevented the occurrence of adenomas among individuals with lower folate status and only
weak indications that any adverse effect of supplementation was enhanced among those with
higher folate status. During the first three years of the study, there was observational evidence
of an inverse association of folate status with risk of all adenomas among placebo subjects, but
no suggestion of a similar pattern among those randomized to folic acid. During the later
follow-up, there were no suggestions of similar patterns. Our findings for advanced lesions
were inconsistent, possibly due to our more limited statistical power for that endpoint.
Folates are hypothesized to have a dual role in colorectal carcinogenesis. They function as
major carriers of the one-carbon groups needed for methylation reactions and nucleotide
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synthesis (14,15). Low folate status may induce DNA hypomethylation, which can affect
maintenance of DNA integrity and stability and expression of oncogenes and tumor suppressor
genes (16). Indeed, high folate levels have been strongly inversely associated with risk of
colorectal neoplasia in several epidemiologic studies (1). Of note is that epidemiologic studies
showing an inverse association of high folates on colorectal adenoma (17–19) or cancer risk
(20,21) have been largely conducted prior to the late 1990's, when fortification of cereal grains
with folic acid in the U.S. and Canada was introduced. As a result of this fortification, there
was a significant increase in circulating levels of plasma folate in the general population (22,
23). Some subsequent studies showed inverse associations of dietary folate and cancer risk
only among non-multivitamin users (24,25), a finding suggests folate may not be protective in
populations that are relatively folate-replete.
In line with these observational studies, we observed suggestive, but non-significant evidence
that higher levels of dietary folate intake and circulating folates may be inversely associated
with risk of any adenoma among individuals in the placebo group during 3 years of follow-up.
There was no evidence of a beneficial effect of high dietary or circulating folates among
individuals randomized to the folic acid group with an indication, at least during the first follow-
up period, of a potential harmful effect. However, these relationships were not apparent during
the second follow-up up to 6 years, possibly because, at this point, more individuals were folate
replete due to fortification of the food supply. Indeed, we observed in our data evidence that
plasma levels of folate increased modestly from baseline to first follow-up in the placebo group,
probably because of the fortification of the North American food supply with folic acid. These
findings support the idea that while folate at moderate doses may be protective compared to
deficiency, at some point of sufficiency there may be no additional benefit with increasing
intake. Interestingly, Song et al. (26) showed in a ApcMin mouse model that dietary folate
supplementation reduced the number of ileal polyps and colonic aberrant crypt foci at 3 months;
however, at later time points (6 months), folate supplementation appeared to increase the
number of ileal polyps. Although the mechanism for this finding is not entirely understood,
the authors suggested that folate deficiency may have caused the regression of established
polyps at later time points.
Additional data provide evidence of the critical importance of the timing of folate exposure.
In a Apc+/- Msh2-/- mouse model, modest doses of folate supplementation given after the
formation of neoplastic foci appeared to increase the development of new foci (27). These data
support the idea that folate under certain circumstances may act to promote carcinogenesis.
There are plausible biological reasons why high levels of folate may promote colorectal
carcinogenesis. Neoplastic cells have a relatively high rate of proliferation (28) and an up-
regulation of folate receptors (29) compared to normal issue. Folates play a key role in the
supply of nucleotides and thereby may facilitate tumor growth (14,15). Furthermore, folic acid
is a pharmaceutical fully oxidized, monoglutamyl form of folate. Folic acid is converted to the
active dihydro- and tetrahydro-forms by dihydrofolate reductase (DHFR). But while small oral
doses of folic acid are efficiently reduced, intakes above 400 µg can saturate DHFR's ability
to convert folic acid (30). As a result, unmetabolized folic acid may be detected in blood after
folic acid supplementation at high doses (30). Unmetabolized folic acid has recently been
associated with reduced natural killer cell cytotoxicity (31). Natural killer cells are part of the
non-specific immune response elicited as a first-line defense mechanism against pathogens or
carcinogenic cells (32). The potential toxicity ascribed to folic acid, as opposed to natural forms
of folate, is conjecture at this point.
In this study, we provide only inconsistent evidence that the associations of folic acid
supplementation with risk of any adenoma or advanced lesions were modified by baseline
dietary and circulating folate levels. This finding provides weak evidence in support of our
initial hypothesis that individuals with high dietary intake or circulating levels of folate may
Figueiredo et al. Page 6













have a greater risk of new adenomas if supplemented with folic acid compared to those with
lower dietary folate intake or circulating levels. Possible explanations include the lack of
statistical power or a threshold effect. Powers et al. provide data from a double-blind
randomized placebo-controlled intervention study of folate and riboflavin supplementation in
healthy colorectal adenoma patients to show that unlike plasma folate, colon mucosal folate
exhibits an upper threshold in response to a moderate folic acid supplementation (33). Their
data suggest than 1,200 µg of folic acid/day for 45 days does not elicit any additional significant
increase in colon folate over 400 µg of folic acid/day. This finding may reflect a regulation of
folate uptake by colonocytes. For example, cellular uptake may be limited by the level of
folylpolyglutamate synthetase (FPGS) which catalyzes folate polyglutamation and thereby
retention of folate (34).
This study has several limitations. The generalizability of our results may be limited as all
participants in this clinical trial were volunteers who had a previous history of at least one
colorectal adenoma. We had a limited sample size to investigate risk of advanced lesions, a
clinically important endpoint. We used a validated semi-quantitative food frequency
questionnaire, but self reported dietary instruments are still subject to measurement error. In
addition, the majority of the subjects were folate-replete as a result of fortification of the food
supply during the recruitment/follow-up time intervals. In comparison to serum and RBC folate
levels determined in two National Health and Nutrition Examination Surveys, one pre-
fortification and one post-fortification, our mean baseline levels are more similar to post-
fortification levels (serum: 26.9 nmol/L and RBC: 590 nmol/L) (35). Lastly, although the
second follow-up interval was analyzed under the intention to treat principle, only 71% of
subjects actually continued their randomization treatment. Furthermore, since individuals in
the second-up could select to be in folate treatment arm this is essentially a cohort study and
potentially subject to bias. To address concerns regarding interval validity, we adjusted our
models for several potential confounders and observed no significant difference in estimates
of risk. To address concerns about external validity, we compared individuals who completed
the first follow-up to those that elected to continue and completed the second follow-up and
observed no substantial differences.
Strengths of this study include the systematic collection of risk factor and dietary information
at baseline and follow-up intervals as well as outcomes at two follow-up intervals. We also
measured both dietary folate (diet only and total intake including supplements) and circulating
levels (plasma and RBC), which allowed us to explore differences in the distribution of folates
across measurements (i.e., dietary, total and circulating). Plasma folate is predominately 5-
MTHF monoglutamate, whereas RBC folate is mostly 5-MTHF polyglutamate, but can
sometimes contain formylated folates (36). Supplemental folate is pterolglutamic acid (folic
acid) which is fully oxidized and bioavailable, and dietary folate is a mixture of polyglutamated
folates, 5-MTHF and 5-formylTHF in combination with certain food constituents (such as
antioxidants) that can influence folate bioavailability (37). For the most part, we observe
consistent findings for dietary, total intake and circulating levels of folate.
In addition, because of the prospective design, recall or selection biases are unlikely to explain
our findings. In addition, inclusion of only individuals with a clear colonoscopy in this
prospective clinical trial, allowed us to assess the effect of folates on incident rather than
prevalent adenomas, and thereby to make clear the temporal relationships between intake and
adenoma occurrence. Furthermore, the high follow-up rates in this study (3) minimize the
concern that differential rates of follow-up affected our results. Uniform, blinded follow-up
also prevented differential ascertainment of endpoints according to folate intake. Furthermore,
the randomized assignment of folic acid substantially reduces the possibility of confounding.
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In this study, we provide no evidence that folic acid supplementation is beneficial in reducing
risk of new adenomas even among individuals with low baseline folates. In addition, we show
suggestive evidence that the protective association of higher folate status is limited to
individuals who are not randomized to folic acid treatment group. These results add to the
growing literature regarding the potential multimodal effects of folic acid supplementation.
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Table 1
Selected characteristics of the study participants§
Characteristic 1st Follow-up 2nd Follow-up
No. of participants 987 776
Age at baseline (mean ± SD), y 57.4 ± 9.5 57.5 ± 9.2
Male Sex, No. 629 (63.7%) 497 (64.1%)
Body-mass index (mean ± SD), kg/m2 27.4 ± 4.6 27.3 ± 4.2
Current cigarette smoker, No. (%) 142 (14.4%) 104 (13.5%)
Colorectal cancer in first-degree relative, No. (%) 304 (38.1%) 249 (39.8%)
Aspirin Treatment Group, No. (%) 657 (66.6%) 515 (66.4%)
Folate Treatment Group, No. (%) 501 (50.8%) 403 (51.9%)
Alcohol (drinks per day), No. (%)
None 299 (31.6%) 225 (30.0%)
1 or less 449 (47.5%) 357 (47.7%)
2 or more 198 (20.9%) 167 (22.3%)
Plasma homocysteine (mean ± SD), µmol/L 9.8 ± 2.9 9.8 ± 2.9
Baseline plasma folate (mean ± SD), nmol/L 23.7 ± 17.4 23.2 ± 17.2
Baseline RBC folate (mean ± SD), ng/ml 322.2 ± 155.9 324.3 ± 155.9
Baseline dietary folate (mean ± SD), mcg/d 322.2 ± 155.9 324.3 ± 155.9
Baseline total folate intake (mean ± SD), mcg/d 458.6 ± 253.0 458.3 ± 246.3
Multivitamin use, No. (%) 354 (35.9%) 276 (35.6%)
Adenoma Characteristics (at baseline)¥
Number (Mean ± SD) 1.57 ± 1.01 1.59 ± 1.01
Large Adenomas (>1 cm), No. (%) 219 (22.2%) 166 (21.4%)
Villous histology, No. (%) 135 (13.7%) 103 (13.3%)
Proximal location, No. (%) 452 (55.8%) 370 (47.7%)
§
counts do not necessarily add to the total sum due to missing data.
¥
using standard definitions by Polyp Prevention Study Group (3, 10);
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